U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis
FDA Orphan Drug Designation (“ODD”) qualifies one-time treatment NXC-201 for: 7 years of U.S. market…
How to Repair Corrupt Exchange Databases Safely and Minimize Downtime
Veea Announces the VeeaONE Distributed Intelligence Platform, Enabling Cybersecure Sovereign Data Fabrics and Enterprise AI Grids for Physical AI